After the bell, shares of the nano-cap had plummeted 10.5% to $1.11.
In the three months to December, the biofuel developer reported a net loss of $17.3 million, or 35 cents a share. Analysts surveyed by Thomson Reuters had expected a net loss of $15.8 million, or 34 cents a share.
Quarterly sales fell 12% to $1.7 million, though beat expectations by $240,000.
Must Read: Warren Buffett's 10 Favorite Stocks
TheStreet Ratings team rates GEVO INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate GEVO INC (GEVO) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share."
- You can view the full analysis from the report here: GEVO Ratings Report